...
首页> 外文期刊>DNA and Cell Biology >lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells
【24h】

lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells

机译:LNCRNA UCA1通过作为慢性髓白血病细胞中的肝癌的CIR-16作用而导致伊马替尼阻力

获取原文
获取原文并翻译 | 示例
           

摘要

Imatinib (IM) has been applied to the chronic phase of chronic myeloid leukemia (CML) and has great benefit on the prognosis of patients with CML. The function of drug efflux mediated by multidrug resistance protein-1 (MDR1) is considered as a main reason for IM drug resistance in CML cells. However, the exact mechanisms of MDR1 modulation in IM resistance of CML cells remain unclear. In the present study, long noncoding RNA (lncRNA) UCA1 was identified as an important modulator of MDR1 by a model system of leukemia cell lines with a gradual increase of MDR1 expression and IM resistance. Overexpression of UCA1 increased MDR1 expression to promote IM resistance of CML cells. Furthermore, for the first time, we demonstrated that UCA1 functions as a competitive endogenous (ceRNA) of MDR1 through completely binding the common miR-16. UCA1-MDR1 might be a novel target for enhancing the therapeutic efficacy of CML patients with IM resistance.
机译:伊马替尼(IM)已应用于慢性骨髓白血病(CML)的慢性阶段,对CML患者的预后具有很大的益处。 通过多药抗性蛋白-1(MDR1)介导的药物流出的功能被认为是CML细胞中耐药性的主要原因。 然而,CML细胞IM电阻中MDR1调节的确切机制仍不清楚。 在本研究中,通过白血病细胞系的模型系统鉴定为MDR1的重要调节剂,其通过白血病细胞系的模型系统鉴定为MDR1表达和电阻的模型系统。 UCA1的过度表达增加了MDR1表达以促进CML细胞的电阻。 此外,我们首次证明UCA1通过完全结合普通miR-16作为MDR1的竞争内源性(Cerna)。 UCA1-MDR1可能是提高CML患者IM抗性的疗效的新靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号